
|Videos|April 17, 2017
Neoadjuvant Treatment Strategies for HER2-Positive Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5










































